|
Acalabrutinib (Tablets) Monotherapy
Regimen
|
00840a
As monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy
00840b
As monotherapy for the treatment of previously untreated CLL in the presence of 17p deletion or TP53 mutation in adult patients unsuitable for chemoimmunotherapy
|
|
Azacitidine 75mg/m2 5-2-2 Therapy
Regimen
|
00287a
Intermediate-1 and low risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS).
00287b
Treatment of adult patients who are not eligible for haematopoietic stem cell transplantation with Intermediate-2 and high risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS).
00287c
Treatment of adult patients who are not eligible for haematopoietic stem cell transplantation with Chronic myelomonocytic leukaemia (CMML) with 10-29% marrow blasts without myeloproliferative disorder.
00287d
Treatment of adult patients who are not eligible for haematopoietic stem cell transplantation with Acute myeloid leukaemia (AML) with20-30% blasts and multi-lineage dysplasia, according to WHO classification.
|
|
azaCITIDine (Oral) Monotherapy
Regimen
|
00818a
Maintenance treatment in adult patients with acute myeloid leukaemia (AML) who achieved complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following induction therapy with or without consolidation treatment and who are not candidates for, including those who choose not to proceed to, haematopoietic stem cell transplantation (HSCT).
|
|
Asciminib Therapy
Regimen
|
00847a
Treatment of adult patients with Philadelphia chromosome positive chronic myeloid leukaemia (Ph+ CML) in the chronic phase (CP), who have previously been treated with two or more tyrosine kinase inhibitors (TKIs).
|
|
azaCITIDine 100mg/m2 5-day Therapy
Regimen
|
00288a
Intermediate-1 and low risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS).
00288b
Treatment of adult patients who are not eligible for haematopoietic stem cell transplantation with Intermediate-2 and high risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS).
00288c
Treatment of adult patients who are not eligible for haematopoietic stem cell transplantation with Chronic myelomonocytic leukaemia (CMML) with 10-29% marrow blasts without myeloproliferative disorder.
00288d
Treatment of adult patients who are not eligible for haematopoietic stem cell transplantation with Acute myeloid leukaemia (AML) with 20-30% blasts and multi-lineage dysplasia, according to WHO classification.
|
|
Bendamustine Monotherapy
Regimen
|
00527a
Treatment of patients with relapsed or refractory Chronic Lymphocytic Leukaemia (CLL)
|
|
Blinatumomab Therapy
Regimen
|
00538a
Treatment of adult patients with relapsed or refractory B cell precursor (BCP) Philadelphia chromosome negative acute lymphoblastic leukaemia (ALL) who have received no prior salvage treatment for relapsed/refractory (R/R) disease and are considered eligible for transplant (i.e. as a bridge-to-transplant).
|
|
Blinatumomab Therapy (ALL with MRD ≥ 0.1%)
Regimen
|
00590a
As monotherapy for the treatment of adults with Philadelphia
chromosome negative CD19 positive B-precursor acute lymphoblastic
leukaemia (ALL) in first or second complete remission with minimal
residual disease (MRD) greater than or equal to 0.1%
|
|
Bosutinib Monotherapy
Regimen
|
00224a
Treatment of adult patients with chronic phase, accelerated phase, and blast phase Ph+CML previously treated with one or more TKI(s) and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.
|
|
Chlorambucil 10mg/m2 Therapy
Regimen
|
00411b
Treatment of patients with Chronic Lymphocytic Leukaemia
|
|
Cladribine 0.14mg/day Day 1 to 5 Therapy
Regimen
|
00402a
First line treatment for adult patients with Hairy Cell Leukaemia
|
|
Cladribine 0.14mg/kg Weekly Therapy
Regimen
|
00469a
First line treatment for adult patients with Hairy Cell Leukaemia
|
|
Cladribine Weekly and riTUXimab Therapy
Regimen
|
00534a
Treatment for adult patients with relapsed or partially responsive Hairy Cell Leukaemia.
|
|
Cladribine 5 day and riTUXimab Therapy
Regimen
|
00531a
Treatment for adult patients with relapsed or partially responsive Hairy Cell Leukaemia.
|
|
Intermediate Dose Cytarabine Therapy
Regimen
|
00364a
Consolidation chemotherapy for the treatment of patients Acute Myeloid Leukaemia (AML)
|
|
High Dose Cytarabine Therapy
Regimen
|
00365a
Consolidation chemotherapy for the treatment of patients with Acute Myeloid Leukaemia (AML)
|
|
DA(60/100) 3+10: Course 1 Induction Therapy (AML-17)
Regimen
|
00359a
Induction chemotherapy regimen for the treatment of patients with de novo or secondary Acute Myeloid Leukaemia (AML)
|
|
DA (50/100) (3+8) Course 2 Induction Therapy (AML-17)
Regimen
|
00360a
Induction chemotherapy regimen for the treatment of patients with de novo or secondary Acute Myeloid Leukaemia (AML)
|
|
Decitabine Monotherapy – AML (28 day cycle)
Regimen
|
00231a
Treatment of adult patients aged 65 years and above with newly diagnosed de novo or secondary AML, according to the WHO classification, who are not candidates for standard induction chemotherapy.
|
|
Fedratinib Therapy
Regimen
|
00788a
For the treatment of disease-related splenomegaly or symptoms in adult patients with:primary myelofibrosis (PMF),post polycythaemia vera myelofibrosis (PVMF) or post essential thrombocythaemia myelofibrosis (ET MF) who are Janus Associated Kinase (JAK) inhibitor naïve or have been treated with ruxolitinib
|
|
FLAG Therapy
Regimen
|
00363a
Treatment of Acute Myeloid Leukaemia (AML) in patients unsuitable for treatment with idarubicin or as consolidation post FLAG-Ida.
00363b
Treatment of patients with high blast count (>10%) Myelodysplastic Syndrome in patients unsuitable for treatment with idarubicin.
00363c
Salvage regimen for patients with relapsed/refractory acute leukaemia.
|
|
FLAG: Ida 8mg/m2 Therapy
Regimen
|
00362a
Induction of chemotherapy regimen for the treatment of patients with de novo, secondary Acute Myeloid Leukaemia (AML), or biphenotypic leukaemia.
00362b
Treatment of patients with blast count (>10%) Myelodysplastic Syndrome
00362c
Salvage regimen for patients with relapsed/refractory acute leukaemia
|
|
Fludarabine, Cyclophosamide and riTUXimab ( FC (IV) and R) Therapy
Regimen
|
00241a
Treatment of B-cell chronic lymphocytic leukaemia (CLL).
|
|
Fludarabine, Cyclophosamide and riTUXimab ( FC (Oral) and R) Therapy
Regimen
|
00410a
Treatment of B-cell chronic lymphocytic leukaemia (CLL).
|
|
Gemtuzumab Ozogamicin, DAUNOrubicin and Cytarabine Therapy (AML induction)
Regimen
|
00612a
Gemtuzumab ozogamicin is indicated for combination therapy with DAUNOrubicin and cytarabine for the treatment of patients age 15 years and above with previously untreated, de novo CD33 positive Acute Myeloid Leukaemia (AML), except acute promyeloytic leukaemia
|
|
Ibrutinib Therapy-CLL - Waldenström’s macroglobulinaemia
Regimen
|
00296a
As a single agent for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy.
00296b
As a single agent for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) in first line in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy.
00296c
As a single agent for the treatment of adult patients with Waldenström’s macroglobulinaemia (WM) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy.
|
|
Idelalisib and riTUXimab Therapy
Regimen
|
00389a
In combination with riTUXimab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy
00389b
In combination with riTUXimab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) as first line treatment in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies
|
|
Inotuzumab ozogamicin Monotherapy
Regimen
|
00537a
Monotherapy for the treatment of adults with relapsed or refractory CD22- positive B cell precursor acute lymphoblastic leukaemia (ALL). Adult patients with Philadelphia chromosome positive (Ph+) relapsed or refractory B cell precursor ALL should have failed treatment with at least 1 tyrosine kinase inhibitor (TKI).
|
|
Midostaurin Maintenance Therapy
Regimen
|
00661a
Midostaurin is indicated as single agent maintenance therapy for adult patients with FLT3 mutation positive acute myeloid leukaemia (AML) in complete response after completion of induction and consolidation chemotherapy
|
|
Midostaurin (DAUNOrubicin and Cytarabine) Induction Therapy
Regimen
|
00682a
Midostaurin is indicated in combination with standard DAUNOrubicin and cytarabine induction chemotherapy for adult patients with newly diagnosed acute myeloid leukaemia (AML) who are FLT3 mutation positive
|
|
Midostaurin and Intermediate Dose Cytarabine Consolidation Therapy
Regimen
|
00683a
Midostaurin is indicated in combination with intermediate dose cytarabine consolidation consolidation chemotherapy for adult patients with newly diagnosed acute myeloid leukaemia (AML) who are FLT3 mutation positive.
|
|
Obinutuzumab and Chlorambucil Therapy
Regimen
|
00286a
Treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) and with comorbidities making them unsuitable for full-dose fludarabine based therapy.
|
|
PONATinib Therapy
Regimen
|
00302a
Treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.
00302b
Treatment of adult patients with Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.
|
|
Ruxolitinib Monotherapy
Regimen
|
The treatment of disease-related splenomegaly or symptoms in adult patients with:
00229a
Primary myelofibrosis (chronic idiopathic myelofibrosis)
00229b
Post polycythaemia vera myelofibrosis
00229c
Post essential thrombocythaemia myelofibrosis
|
|
Tretinoin (ATRA) with Arsenic Trioxide (ATO) Induction Therapy
Regimen
|
00356a
Treatment of patients with newly diagnosed low to intermediate risk Acute Promyelocytic Leukaemia (APL)
00356b
Treatment of adult patients with relapsed or refractory APL after ATRA/chemotherapy.
|
|
Tretinoin (ATRA) with Arsenic Trioxide (ATO) Consolidation Therapy
Regimen
|
00357a
Treatment of patients with low to intermediate risk Acute Promyelocytic Leukaemia (APL) with haematological complete remission (CR) after induction treatment with tretinoin (ATRA) and arsenic trioxide (Ref NCCP Protocol 00356).
|
|
Tretinoin (ATRA)IDArubicin (PETHEMA AIDA) Induction Therapy:High Risk
Regimen
|
00366a
Treatment of patients with newly diagnosed high risk Acute Promyelocytic Leukaemia (APL)
|
|
Venetoclax Monotherapy
Regimen
|
00400a
Treatment of chronic lymphocytic leukaemia (CLL) in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor.
00400b
Treatment of CLL in the absence of 17p deletion or TP53 mutation in adult patients who have failed both chemoimmunotherapy and a B-cell receptor pathway inhibitor
|
|
Venetoclax and obinutuzumab Therapy
Regimen
|
00715a
In combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).
|
|
Venetoclax and riTUXImab Therapy
Regimen
|
00575a
Venetoclax in combination with riTUXimab is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy
|
|
Vyxeos liposomal® DAUNOrubicin and Cytarabine Induction Therapy
Regimen
|
00613a
For the treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC)
|
|
Vyxeos liposomal® DAUNOrubicin and Cytarabine Consolidation Therapy
Regimen
|
00618a
For the treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC)
|
